NCT07020923 Phase 2 Active not recruiting
Monthly Dosing of Atacicept in IgAN Study sponsor: Vera Therapeutics, Inc. · VERA
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2026-09 Estimated
Enrollment · participants 90 Estimated
Source updated 2026-04-13 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2026-04-13 · 1 field changed
Recruitment status Recorded edit − Previous value Recruiting
+ Updated value Active not recruiting
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology